___ 5. Alternatives (if applicable): It is specified whether there are proven, established treatment options available that may be advantageous to the subject (in lieu of the study treatment).

___ 6. Contacts: The names and telephone numbers of all investigators and hours available.

___ 7. Performance Sites: Where the study will be conducted.

___ 8. Number of Subjects: Maximum number of subjects anticipated including controls if relevant.

___ 9. Subjects:

___ A. Inclusion Criteria: All criteria for participation in the study are specified. Examples: >18 years old, left or right-handed, diagnosed with a specified condition; Subject pool, e.g. psychology undergraduate students, senior citizens, etc.

___ B. Exclusion Criteria: Specify any subset of those meeting the inclusion criteria to be excluded from the study.

___ 10. Privacy: Specify whether the study is anonymous or confidential. An anonymous study is one in which the data cannot be linked to the identity of the subject directly or indirectly – either because the name/identity of the subject is never obtained by the investigator, or because there is no code linking data to the subject's identity. If the study is not anonymous, i.e., if there is a code linking data to identity, describe the extent, if any, to which confidentiality of records identifying the subject will be maintained. Confidentiality cannot be absolute. Always state “data will be kept confidential unless release is legally compelled.”

____ 11. Financial Information: Any compensation for participating and any uncompensated costs incurred by subjects are specified. State when incentives will be delivered.

____ 12. Right to Refuse: State participation in the study is voluntary and subjects may change their mind and withdraw from the study at any time without penalty or loss of any benefit to which they may otherwise be entitled.

Numbers 13-15 must be included in a consent form when a subject enters an experimental medical or behavioral treatment program. To explore the potential to remedy a condition from which he/she suffers.

___ Check here if not applicable and skip to #16. Otherwise, answer each question with yes or no. "No" indicates a consent form deficiency which must be remedied before the IRB application can be approved.

___ 13. Unforeseeable Risks: Specify the treatment or procedure may involve risks to the subject (or the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable.eea

___ 14. Study-associated injury or illness:

___ A. Any compensation or medical care which will be arranged for or provided by the investigators is described.

___ B. Subjects are informed what to do and whom they are to notify in the event of a study-related illness or injury.

___ 15. New Findings: Significant new findings developed from the study data or independent sources during the course of the research which may relate to the subject’s willingness to continue participation (e.g., adverse response to the treatment) will be explained to the subjects.

Numbers 16-17 must be included in a consent form when a subject's failure to complete a study will deprive the subject of benefit (including)] 0 Tm 2.5 -9.( )Tj -0.